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Summary
Background Early diagnosis interventions such as symptom awareness campaigns increasingly form part of global 
cancer control strategies. However, these strategies will have little impact in improving cancer outcomes if the 
targeted symptoms represent advanced stage of disease. Therefore, we aimed to examine associations between 
common presenting symptoms of cancer and stage at diagnosis.
Methods In this cross-sectional study, we analysed population-level data from the English National Cancer Diagnosis 
Audit 2014 for patients aged 25 years and older with one of 12 types of solid tumours (bladder, breast, colon, 
endometrial, laryngeal, lung, melanoma, oral or oropharyngeal, ovarian, prostate, rectal, and renal cancer). We 
considered 20 common presenting symptoms and examined their associations with stage at diagnosis (TNM stage IV 
vs stage I–III) using logistic regression. For each symptom, we estimated these associations when reported as a single 
presenting symptom and when reported together with other symptoms.
Findings We analysed data for 7997 patients. The proportion of patients diagnosed with stage IV cancer varied 
substantially by presenting symptom, from 1% (95% CI 1–3; eight of 584 patients) for abnormal mole to 80% (71–87; 
84 of 105 patients) for neck lump. Three of the examined symptoms (neck lump, chest pain, and back pain) were 
consistently associated with increased odds of stage IV cancer, whether reported alone or with other symptoms, 
whereas the opposite was true for abnormal mole, breast lump, postmenopausal bleeding, and rectal bleeding. For 
13 of the 20 symptoms (abnormal mole, breast lump, post-menopausal bleeding, rectal bleeding, lower urinary tract 
symptoms, haematuria, change in bowel habit, hoarseness, fatigue, abdominal pain, lower abdominal pain, weight 
loss, and the “any other symptom” category), more than 50% of patients were diagnosed at stages other than stage IV; 
for 19 of the 20 studied symptoms (all except for neck lump), more than a third of patients were diagnosed at stages 
other than stage IV.
Interpretation Despite specific presenting symptoms being more strongly associated with advanced stage at diagnosis 
than others, for most symptoms, large proportions of patients are diagnosed at stages other than stage IV. These 
findings provide support for early diagnosis interventions targeting common cancer symptoms, countering concerns 
that they might be simply expediting the detection of advanced stage disease.
Funding UK Department of Health’s Policy Research Unit in Cancer Awareness, Screening and Early Diagnosis; 
and Cancer Research UK.
Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
Globally, cancer control strategies increasingly encompass 
the early diagnosis of symptomatic cancer alongside 
primary prevention policies and screening programmes.1,2 
Several countries have introduced health system 
interventions that aim to expedite investigation and 
diagnosis of symptomatic individuals presenting in 
primary care, whereas public health education campaigns 
aimed at raising awareness of cancer symptoms are 
increasingly being used both in high-income countries 
and in low-income and middle-income countries 
(appendix p 2).3–7
By their nature, early diagnosis interventions focus on 
the presenting symptoms of cancer. If the selected 
symptoms predominantly represent advanced-stage 
disease, however, these initiatives might have little 
impact in improving cancer outcomes. Understanding 
associations between presenting symptoms of cancer 
and stage at diagnosis is therefore an important 
consideration.2
Existing evidence about associations between presenting 
symptoms and stage at diagnosis is scarce and confined to 
specific cancer sites,8–15 overlooking the fact that some 
symptoms at presentation (particularly those of a non-
specific nature) are shared among different types of cancer; 
for example, abdominal pain is a common symptom of 
colorectal, ovarian, and renal cancer.16 Furthermore, 
symptoms are typically examined as being either present 
or absent, without consideration of the possible additive or 
interactive effects of multiple symptoms.
In this study, we therefore aimed to examine asso-
ciations between common presenting symptoms of 
cancer and stage at diagnosis, using data from a 
population-based incident cohort of patients with cancer.
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Methods
Study design and participants
For this cross-sectional, population-based study we 
analysed data of patients included in the National Cancer 
Diagnosis Audit (NCDA) in England.17 As described 
previously, general practitioners (GPs) and other health-
care professionals in participating general practices 
provided information about the diagnostic pathway of 
patients identified as having been diagnosed with a 
malignant neoplasm in 2014 by Public Health England’s 
National Cancer Registration and Analysis Service 
(NCRAS). The data were collated by NCRAS under 
regulation 2 of the Health Service (Control of Patient 
Information) Regulations 2002 legislation. Ethical 
approval for this study was obtained by the London 
Hampstead Research Ethics Committee (REC reference: 
8/LO/0377).
439 general practices (comprising approximately 5% 
of all practices in England) submitted data on 
17 042 tumour records. The sex, age, and cancer site 
distribution of included patients was representative of 
the contemporary national incident cohort.17 
Furthermore, participating practices were similar to 
non-participating practices with regard to their 
demographic case-mix, patient experience scores, and 
referral rates for suspected cancer, but served slightly 
larger registered populations.17
We restricted our study population to symptomatic 
adult patients aged 25 years and older, diagnosed with 
one of 12 solid tumours with a high degree (≥85%) of 
stage completeness (in descending order): endometrial 
(95% complete staging), lung, rectal, breast, melanoma, 
prostate, colon, renal, bladder, ovarian, oral or 
oropharyngeal, or laryngeal cancer (85% complete 
staging), representing 79% of incident cases of solid 
tumours in England in the study year 201418 (see 
appendix p 3 for the list of excluded cancers).
Procedures
Information about stage at diagnosis in the study popu-
lation was available from NCRAS as TNM stage I–IV; we 
defined advanced stage as TNM stage IV (see below for 
alternative categorisation of stage at diagnosis).
Information about presenting symptoms (specified as 
symptoms noted at first presentation before diagnosis 
and referral) was provided by participating GPs based on 
health records using a list of 81 prespecified symptoms 
(in “yes” and “no” format). We examined 19 symptoms 
recorded in at least 50 patients: abnormal mole, 
abdominal pain, back pain, breast lump, chest infection, 
chest pain, change in bowel habit, cough, dyspnoea, 
fatigue, haematuria, haemoptysis, hoarseness, lower 
abdominal pain, lower urinary tract symptoms, neck 
lump, post-menopausal bleeding, rectal bleeding, and 
weight loss. All other symptoms (n=59) were considered 
together in a 20th “any other symptom” category 
(appendix p 4). Therefore, patients could have a single 
presenting symptom or multiple symptoms (one or more 
of the above symptoms in any combination).
Statistical analysis
We estimated the proportion of patients diagnosed at 
stage IV by single or multiple symptom status for each of 
the 20 symptoms. Because patients with different cancers 
often present with the same symptom,16 we examined 
the cancer site case-mix of each presenting symptom 
(namely, the proportion of patients with different cancers 
that are diagnosed following presentation with a parti-
cular symptom) to aid interpretation of our findings 
(see appendix pp 5–6 for cancer site signatures of all 
20 symptoms).
Subsequently, we examined patient-level associations 
between symptoms and stage at diagnosis using logistic 
regression (stage IV vs stages I–III). Ideally, we would 
have studied associations between every symptom 
Research in context
Evidence before this study
We searched PubMed for articles published between 
Jan 1, 1980, and Jun 17, 2019, using the search terms 
“presenting symptom” or “symptom” AND “cancer” AND 
“stage”, with additional hand-searching of reference lists of 
identified papers and relevant subject reviews. We identified 
12 studies on single cancer sites (five on ovarian cancer, 
three on colon or colorectal cancer, one on lung cancer, one on 
anal cancer, one on pancreatic cancer, and one on renal cancer), 
of which three examined associations between presenting 
symptoms and stage, adjusting for possible confounders. 
Only one study (on patients with colorectal cancer) considered 
both single presenting symptoms and symptom combinations.
Added value of this study
These findings characterise associations between common 
presenting symptoms and stage at diagnosis in a 
population-based incident cohort of patients with different 
cancers. For 13 of the 20 studied symptoms, more than 50% 
of patients were diagnosed with cancer at stages other than 
stage IV, and for 19 symptoms (all except for neck lump) 
more than a third were diagnosed at a stage other than 
stage IV.
Implications of all the available evidence
Common presenting symptoms have variable associations 
with advanced stage at diagnosis, although for all symptoms 
analysed in this cross-sectional study we found that large 
proportions of patients are diagnosed at stages other than 
stage IV. Early diagnosis initiatives such as public health 
campaigns aimed at raising awareness of possible symptoms 
of cancer and clinical guidelines for the assessment and 
investigation of patients with symptoms have the potential 
to help detect cancer at a non-advanced stage.
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combination (each pair, triplet, and so on) and stage at 
diagnosis, because the presence of additional symptoms 
could affect a given symptom’s association with the 
outcome of interest; however, this approach was not 
feasible given the large number of symptom combi-
nations relative to the sample size. Instead, we modelled 
each presenting symptom as a pair of binary variables: 
one denoting its presence or absence, and the other 
denoting its presence or absence when recorded with 
other symptoms. Since we did not examine patients 
without symptoms, the constant was constrained to 0, 
fixing the baseline odds of stage IV to 1.
For each symptom, two odds ratios (ORs) could be 
estimated from the above model for each symptom: 
“single” and “multiple”. The single OR represents the 
association of a given symptom with stage at diagnosis 
when seen alone, compared with change in bowel habit 
(used as the reference category, since this was the most 
common symptom in the study population). 
Furthermore, by adding the coefficients from the first 
and second binary variables for each symptom, we 
estimated a multiple OR for each symptom, which 
represents its association with cancer stage when seen 
together with one or more of the other 19 symptom 
categories, compared with patients with multiple 
symptoms other than the symptom of interest. An 
OR value of 1 implies that stage at diagnosis is no 
different between patients with and without the symptom 
of interest among those with multiple symptoms.
We also adjusted for age group (categorised as 
25–49 years, 50–59 years, 60–69 years, 70–79 years, and 
≥80 years), sex (male vs female), index of multiple 
deprivation income domain quintiles (from 1 to 5, with 
1 being least deprived and 5 being most deprived), 
ethnicity (white, non-white, and missing), and cancer 
site (12 solid tumour sites, as described above). The 
events per variable criterion for sample size 
considerations was satisfactory.19
We did four sensitivity analyses. For the first, we 
repeated the main analysis by categorising advanced 
stage as stage III–IV, compared with stage I–II disease.
The second sensitivity analysis comprised an extreme 
case scenario for missing information about stage. 
Unlike with missing exposure variable data, a complete 
case analysis (CCA) where only outcome variable data 
are missing (as is the case for stage at diagnosis in our 
study) is unbiased assuming the missing at random 
mechanism. Multiple imputation can make the 
assumption of data missing at random more reasonable 
than it would be under CCA only if auxiliary variables 
that are absent from the analysis model are used in the 
imputation model;20 however, no such variables were 
available and so the imputation model would have been 
of no value. Therefore, we did an extreme case 
sensitivity analysis in which all patients with missing 
stage information were assumed to have stage IV 
cancer. Although this extreme scenario is unlikely to be 
realistic, we can be reasonably confident that the true 
bias in our findings will be lower than that illustrated 
with this analysis.21
The third sensitivity analysis involved repeating the 
main analysis by restricting it to patients who had a 
diagnostic interval (time from symptomatic presentation 
to diagnosis) of 0–60 days, since time to diagnosis could 
influence the association between presenting symptoms 
and stage.22
For the fourth sensitivity analysis, we adjusted for 
route to diagnosis as the association between route 
to cancer diagnosis (a patient’s health-care utili-
sation pathway before diagnosis) and stage might 
also influence the association of interest.23 Therefore, 
the main analysis was repeated with further adjust-
ment for route to diagnosis among patients with 
complete information about their diagnostic route.24 
Specifically, we considered the following five diagnostic 
route categories: 2-week-wait referral (urgent referrals 
for suspected cancer from primary care to specialist 
hospital services in the UK), elective referral (routine, 
non-urgent referrals), emergency presentation, secon-
dary care (both inpatient and outpatient) routes, and 
unknown route.
All analyses were done with Stata SE, version 15.1.
12 927 patients with non-screen detected cancer
 with complete information on symptoms 
1291 excluded (diagnosed with leukaemia,
 lymphoma, myeloma, or brain cancer) 
11 636 patients
2717 excluded (patients with cancer sites
 where >15% of patients had no 
 information on stage* or were diagnosed
 with stage 0†)
8919 patients
26 excluded (aged 0–24 years)
8893 patients
896 excluded (with missing stage information)
7997 patients included in final analysis
Figure 1: Study population
*n=2707. †n=10.
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Role of the funding source
The funders of the study had no role in study design, 
data collection, data analysis, data interpretation, or the 
writing of the report. The corresponding author had full 
access to all the data in the study and had final 
responsibility for the decision to submit for publication.
Results
From an initial cohort of 12927 patients with non-screen 
detected cancers included in the NCDA 2014, we analysed 
data for 7997 patients diagnosed with solid tumours with 
high stage completeness (figure 1). Breast lump was 
the most common presenting symptom, reported in 
1260 patients in our study sample, and neck lump was the 
least common, reported in 105 (table). A third of all 
patients (2685 of 7997; 34% [95% CI 33–35]) had two or 
more symptoms; symptoms varied in their likelihood of 
being seen alone or with other symptoms (figure 2).
Some, typically localised, symptoms had relatively 
narrow cancer site signatures where the majority (>80%) 
of patients were diagnosed with the same cancer site, 
such as breast lump (breast cancer), abnormal mole 
(melanoma), post-menopausal bleeding (endometrial 
cancer), lower urinary tract symptoms (prostate cancer), 
and haemoptysis, dyspnoea, chest infection, chest pain, 
and cough (lung cancer). By contrast, less specific 
symptoms such as abdominal pain, change in bowel 
A
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Figure 2: Presenting symptoms and proportions of patients with stage I–III and stage IV cancer
The first bar of each pair for each symptom represents symptoms recorded alone (single symptoms), whereas the 
second bar of each pair represents symptoms recorded with other symptoms (multiple symptoms).
Overall Symptoms reported alone Symptoms reported with other symptoms
Total (n) Stage IV 
(n)
Stage IV 
(%; 95% CI)
Total (n) Stage IV 
(n)
Stage IV 
(%; 95% CI)
Total (n) Stage IV 
(n)
Stage IV 
(%; 95% CI)
Abnormal mole 584 8 1% (1–3) 564 7 1% (1–3) 20 1 5% (0–25)
Breast lump 1260 58 5% (4–6) 1074 36 3% (2–5) 186 22 12% (8–17)
Postmenopausal bleeding 292 17 6% (3–9) 229 9 4% (2–7) 63 8 13% (6–23)
Rectal bleeding 498 80 16% (13–20) 215 28 13% (9–18) 283 52 18% (14–23)
Lower urinary tract 
symptoms
1135 210 19% (16–21) 805 121 15% (13–18) 330 89 27% (22–32)
Haematuria 487 101 21% (17–25) 322 57 18% (14–22) 165 44 27% (20–34)
Change in bowel habit 819 236 29% (26–32) 186 46 25% (19–32) 633 190 30% (26–34)
Lower abdominal pain 285 83 29% (24–35) 51 18 35% (22–50) 234 65 28% (22–34)
Any other symptom 2433 873 36% (34–38) 876 265 30% (27–33) 1557 608 39% (37–42)
Abdominal pain 424 156 37% (32–42) 89 29 33% (23–43) 335 127 38% (33–43)
Hoarseness 124 51 41% (32–50) 68 21 31% (20–43) 56 30 54% (40–67)
Fatigue 365 170 47% (41–52) 58 18 31% (20–45) 307 152 50% (44–55)
Weight loss 584 287 49% (45–53) 71 27 38% (27–50) 513 260 51% (46–55)
Cough 672 361 54% (50–58) 161 72 45% (37–53) 511 289 57% (52–61)
Haemoptysis 179 97 54% (47–62) 59 33 56% (42–69) 120 64 53% (44–62)
Chest infection 317 176 56% (50–61) 63 34 54% (41–67) 254 142 56% (50–62)
Dyspnoea 513 289 56% (52–61) 108 52 48% (38–58) 405 237 59% (54–63)
Back pain 269 163 61% (54–66) 107 62 58% (48–67) 162 101 62% (54–70)
Chest pain 293 181 62% (56–67) 83 50 60% (49–71) 210 131 62% (55–69)
Neck lump 105 84 (80% (71–87) 65 52 80% (68–89) 40 32 80% (64–91)
Symptom rows are ordered by overall proportion of patients with stage IV cancer.
Table: Observed proportions of stage IV cancer associated with 20 presenting symptoms (overall, as a single symptom, and as one of multiple 
symptoms) in patients diagnosed with one of 12 cancers (n=7997)
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habit, back pain, fatigue, and weight loss had more 
diverse cancer site signatures (appendix pp 5–6).
The proportion of patients diagnosed at stage IV by 
symptom varied from 1% (95% CI 1–3; eight of 
584 patients with an abnormal mole) to 80% (71–87; 84 of 
105 patients with a neck lump; table, figure 2). For 13 of 
the 20 symptoms, more than 50% of patients were 
diagnosed with non-advanced stage cancer, while for all 
symptoms apart from neck lump, more than a third (at 
least 38%) were diagnosed at stages other than stage IV 
(table, figure 2).
The pattern of variation in symptom-specific 
associations with stage IV disease when reported alone 
(figure 3) was similar to the associations seen for 
symptoms when reported with other symptoms (both χ² 
p<0·0010; appendix pp 7–9). Three symptoms (neck 
lump, chest pain, and back pain) were consistently 
associated with an increased odds of stage IV disease, 
whereas abnormal mole, breast lump, post-menopausal 
bleeding, or rectal bleeding were associated with lower 
odds of stage IV disease (appendix p 8).
Adjusting for patient characteristics and cancer site 
made little difference to the order of symptom-specific 
odds of stage IV disease for both single and multiple 
symptoms, although effect sizes were generally smaller 
(figure 3; appendix pp 7–10).
Additional sensitivity analyses examining differences 
in categorisation of stage (categorising advanced stage as 
stage III–IV), an extreme case scenario for missing 
information on stage, stratification by diagnostic interval 
(restricting the analysis to those with a diagnostic interval 
of 0–60 days), and additional adjustment for route to 
diagnosis also provided similar findings (appendix 
pp 11–20).
Discussion
In our population-based cohort of patients with cancer, 
certain presenting symptoms, such as neck lump, had 
stronger associations with stage IV disease than others, 
but for most symptoms we found that large proportions 
of patients were diagnosed at stages other than stage IV. 
The relative order of symptom-specific associations was 
broadly comparable whether symptoms were seen alone 
or with other symptoms. Adjustment for confounders 
including cancer site made little difference to the overall 
pattern of associations between symptoms and stage at 
diagnosis.
With regard to associations between presenting 
symptoms and stage at diagnosis, direct comparisons 
with existing literature are challenging because published 
studies are cancer-site specific. Evidence from such 
studies provides an incomplete picture of associations 
between presenting symptoms and stage at diagnosis, 
because individuals who present with the same symptoms 
could be diagnosed with cancers of different sites. By 
contrast, in this study, we evaluated the presenting 
symptoms of patients with a range of common and rarer 
cancers and examined associations with and without 
adjustment for the case-mix of cancer sites in our study 
population. Nevertheless, in previous studies, among 
patients with colorectal cancer, rectal bleeding has been 
associated with earlier stage at diagnosis compared with 
abdominal pain and change in bowel habit,9,14 whereas in 
patients with ovarian cancer, gastrointestinal symptoms 
(including abdominal pain, digestive bowel symptoms, 
and distension) have been more strongly associated with 
advanced stage cancer than gynaecological symptoms 
such as vaginal bleeding.8,10
Except for one published study (which examined three 
symptoms and their combinations with stage14), the 
existing literature does not differentiate symptoms 
according to when they are reported on their own or 
when they are reported with other symptoms. By contrast, 
our study characterised associations between symptoms 
and stage, both when a symptom was reported alone and 
when it was reported together with other symptoms, 
which allowed us to adjust for potential interactions 
between all possible symptom combinations.
A key strength of our study is that it examined the 
association between presenting symptoms and stage in a 
well-characterised population-based incident cohort of 
patients with different cancers. The NCDA represents a 
unique combination of information provided by GPs and 
other health-care professionals based on clinical insight 
and judgment, with high-quality information about 
patient and tumour characteristics from the national 
cancer registry in England.17,25
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Figure 3: Odds ratios of stage IV disease by presenting symptoms seen alone
Odds ratios of stage IV disease by symptom without adjustment (blue); and with adjustment for sex, age group, 
ethnicity, IMD quintile, and cancer diagnosis (red). Data shown for 7997 patients with one of 12 cancers. Error bars 
represent 95% CIs; the dashed line represents the value of the reference group (patients with change in bowel 
habit). For odds ratios of symptoms when reported with other symptoms, see appendix p 9.
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In addition to adjusting our findings by socio-
demographic factors, we adjusted our results by cancer 
site. Although this adjustment did not appear to 
substantially alter the observed patterns of variation, the 
associations between symptoms and stage at diagnosis 
might differ in a population-based incident cohort with a 
different distribution of cancer sites.
Our study does have some potential limitations. As is 
the case for other studies based on clinical audits of 
cancer diagnosis,26–28 elicitation and recording of 
symptoms during the index consultation, and subsequent 
extraction of information from primary care records, 
might be incomplete and prone to bias.29 Nevertheless, 
alternative approaches based on self-reported data from 
individuals diagnosed with cancer are susceptible to 
under-representation of patients with a poor prognosis.30 
With either method, it is possible that some of the 
recorded symptoms might relate to concomitant chronic 
illness, especially in patients with multiple symptoms. 
However, the observed distribution of cancer sites among 
patients with specific symptoms concord with previous 
knowledge about the presenting symptoms of each 
cancer site. This observation provides a strong indication 
that the recorded information about presenting 
symptoms chiefly relates to the subsequently diagnosed 
cancer site rather than other conditions.
The study population represents around four-fifths of 
patients diagnosed with solid tumours in England during 
2014.18 Among the cancer sites included in the study, a 
small proportion of patients with missing stage 
information were excluded from analyses, variably by 
cancer site. However, sensitivity analyses, which would 
demonstrate the effect of maximum possible bias arising 
from missing data (ie, by assigning patients with missing 
stage information to stage IV) provided similar findings 
to our main analysis.
Our findings refute concerns that early diagnosis 
interventions centred on common presenting symptoms 
of cancer would typically expedite the diagnosis of 
individuals with stage IV disease. Rather, they indicate 
that a substantial proportion of patients with these 
symptoms are diagnosed with non-advanced disease, 
which is associated with potentially good prognosis. This 
finding was the case even for patients with symptoms 
most strongly associated with advanced stage in our 
study, and for symptoms often considered indicative of 
advanced disease, such as weight loss.
Furthermore, evaluation of the effect of single and 
multiple symptoms separately indicates that the presence 
of multiple symptoms is a poor predictor of stage IV 
disease. The nature of the symptom appears to be more 
important than the number of reported symptoms. This 
observation is reassuring, given that public health 
education campaigns typically do not focus on symptom 
combinations.
Symptom awareness and appraisal by patients 
and doctors is an important determinant of timely 
presentation and investigation31–34 but the optimal design 
of early diagnosis interventions aimed at earlier 
recognition of possible cancer symptoms by members of 
the public and health-care professionals remains 
unclear. Alongside considerations such as cancer site 
incidence, psychosocial barriers to presentation, and the 
predictive value of symptoms, evidence about the 
associations between presenting symptoms and stage at 
diagnosis can help to guide the design of early diagnosis 
interventions. Our findings provide support for such 
interventions, and counter concerns that they simply 
expedite the detection of advanced-stage disease.
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